Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET)

TLDR: This research highlights the need to understand more fully the role of “cell reprograming” in the development of Parkinson’s disease and its role in cancer.

Abstract: EVMS Strelitz Diabetes Research Center and Neuroendocrine Unit, Norfolk, VA; University Hospital Gasthuisberg, Leuven, Belgium; University Hospital Timone, Paoli-Calmettes Institute and RENATEN Network, Marseille, France; Paoli-Calmettes Institute, Marseille, France; Seoul National University Hospital, Seoul, Republic of Korea; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; The Christie NHS Foundation Trust, Manchester, United Kingdom; McGill University Hospital Centre, Montreal, QC, Canada; Medical oncology, University Hospital, Bordeaux, France; Chang Gung Memorial Hospital and Chang Gung University, Taipei, Republic of China; Zentralklinik Bad Berka GmbH, Bad Berka, Germany; Hospital Universitario 12 de Octubre, Madrid, Spain; British Columbia Cancer Agency, Vancouver, BC, Canada; Washington University School of Medicine, St. Louis, MO; University of Western Australia, Perth, Australia; Pfizer Oncology, La Jolla, CA; Beaujon University Hospital, Clichy, France